The Scientific Research Team at Oric Pharmaceuticals focuses on elucidating the mechanisms of cancer therapy resistance and developing innovative treatments to counteract these mechanisms. This team conducts advanced preclinical and clinical research, including in vivo pharmacology, bioinformatics analyses, and medicinal chemistry, to support the discovery and optimization of novel oncology therapeutics. Their efforts are crucial in advancing ORIC’s lead assets, such as ORIC-101, and expanding the company's pipeline of resistance-targeting cancer treatments.
Bob Warne
Senior Principal Scientist
Brian Blank
Principal Scientist
Chelsea Chen
Scientist
Christopher Weber
Senior Scientist
Claire Repellin
Principal Scientist
Daniel Holycross
Senior Scientist, Process Chem...
Daniel Shore
Senior Scientist, Medicinal Ch...
Idil Ulengin-Talkish
Senior Scientist
Rakesh Vekariya
Senior Scientist, Medicinal Ch...
Siobhan K. McRee
Senior Scientist
View all